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Background: The FimA of Porphyromonas gingivalis is a cru-
cial pathogenic component of the bacteria and has been im-
plicated as a target for vaccine development against the pe-
riodontal diseases. Methods: In this study, the purified fim-
briae (FimA subunit polymers) protein was used for immuni-
zation in their native form and B hybridoma clones producing 
antibodies specific to FimA were established. Results: The 
monoclonal antibodies prepared from selected two clones, 
designated #123 (IgG2b/ kappa) and #265 (IgG1/kappa), 
displayed different patterns of binding activity against the 
cognate antigen. Both antibodies reacted with conforma-
tional epitopes expressed by partially dissociated oligomers, 
but not with monomer as elucidated by Western blot 
analysis. Ascites fluid containing the monoclonal antibodies 
showed the inhibitory activity against P.  g i n g i v a l i s  to sali-
va-coated hydroxyapatite beads, an in vitro model for the 
pellicle-coated tooth surface. Conclusion: These results sug-
gest that the monoclonal antibodies could be used as vaccine 
material against the periodontal diseases through passive 
immunization.
[Immune Network 2009;9(5):203-207]
INTRODUCTION
Periodontitis is a common oral inflammatory disease charac-
terized by redness and bleeding of gingival tissue, resorption 
of alveolar bone and tooth loss (1,2). Porphyromonas gingi-
valis, a black pigmented gram-negative anaerobic bacterium, 
is one of the major pathogens in periodontitis (3). The viru-
lence of P. gingivalis has been known to be caused by vari-
ous factors including hemagglutinins, cystein proteinases, ag-
gregation factors, lipopolysaccharides, and fimbriae and those 
factors are characterized to be responsible for bacterial colo-
nization  (4,5).
    Several reports have indicated that fimbriae, one of the vir-
ulent factors, are important for mediating adherence to host 
tissues and other oral bacteria, and, consequently, are consid-
ered as a promising candidate antigen for vaccine develop-
ment (6-9). This consideration was supported by the report 
that immunization of rat animal model with purified P. gingi-
valis fimbriae or synthetic peptide induced the protective im-
m u n i t y  a g a i n s t  p e r i o d o n t a l  d e s truction  (10,11).  In  addition, 
FimA, a major subunit of P. gingivalis fimbriae with a molec-
ular mass of 43 kDa, is considered as a major target for vac-
cine development based on the observation that monoclonal 
antibody  against  FimA  blocked  adhesion  of  the  bacteria  to 
human  buccal  epithelial  cells  (12,13).
    Passive immunization using antibodies against the specific 
pathogens  has  advantages  of  immediate-immune  response, 
low  toxicity,  and  high  specific  activity  against  the  infection 
(14). In human, passive immunization using antibody against 
Streptococcus  mutans  prevented  bacterial  recolonization  for 
up to 2 years (15). In this study, as an attempt to develop 
monoclonal antibody specific to FimA for passive immuniza-
tion against P. gingivalis infection, we established the hybrid-
oma  clones  expressing  anti-FimA  monoclonal  antibody.  In 
addition, their inhibitory activity against the bacterial binding FimA mAb Production
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onto  oral  surface  was  assessed  using  hydroxyapatite  bead 
assay.
MATERIALS AND METHODS
Purification of fimbriae protein from P. gingivalis
Fimbriae of P. gingivalis 2561 was purified according to the 
method described by Lee et al (16). Briefly, after harvesting 
cells of P. gingivalis strain 2561, the bacterial cells were sub-
jected  to  mild  ultrasonication  (Vibra  Cell,  Model  VC-600, 
Sonic and Materials Inc., Danbury, CT). After ultrasonication, 
crude  fimbriae  of  the  sonic  extract  were  obtained  by  ce-
ntrifugation. The fimbriae-containing supernatant was brought 
to  40%  saturation  by  stepwise  addition  of  solid  ammonium 
sulfate  and  stirred  at  4
oC  overnight.  The  precipitated  crude 
fimbrial extract was dialyzed and clarified by centrifugation. 
The clarified crude fimbrial extract was mixed with guanidine 
HCl (UltraPURE, enzyme grade; BRL, Gaithersburg, MD) and 
subjected to gel filtration on a Sepharose CL-6B (Pharmacia 
Biotech,  Sweden)  column  equilibrated  with  6  M  guanidine 
HCl. The fimbriae were purified by repeated Sepharose col-
umn chromatography. Homogeneity of the purified fimbrial 
protein  was  determined  by  SDS-polyacrylamide  gel  electro-
phoresis  (SDS-PAGE).
Preparation of B hybridoma clones
S y n g e n e i c  B A L B / c  m i c e  w e r e  p u r c h a s e d  f r o m  O r i e n t  B i o  
(Sungnam,  Korea)  and  immunized  with  20  g/mouse  FimA 
protein  emulsified  with  complete  Freund’s  adjuvant.  The 
s a m e  m i c e  w e r e  b o o s t e d  w i t h  t h e  s a m e  a n t i g e n  e m u l s i f i e d 
with incomplete Freund’s adjuvant. The spleen cells of immu-
nized  mice  were  fused  with  SP2/0  myeloma  cells  (ATCC, 
Manassas, VA) at a ratio 1：1 using PEG 1500 (Roche Dia-
gnostics GmbH., Mannheim, Germany). The fused cells were 
spread  onto  96-well  culture  plates  in  Dulbecco’s  modified 
Eagle’s  medium  (Hyclone  Laboratories,  Logan,  UT)  supple-
mented  with  HAT  and  20%  FBS  (PAA,  Etobicoke,  Ontario, 
Canada). Generated hybridoma clones were subcloned three 
times by limiting dilution procedure and the binding specific-
ity of the antibodies produced by the hybridoma clones were 
determined  through  ELISA  and  Western  blot  analyses.
Determination of antibody specificity and isotypes
Specificity  of  antibodies  produced  from  established  hybrid-
o m a  c l o n e s  w a s  d e t e r m i n e d  b y  E L I S A  a n d  W e s t e r n  b l o t  
analyses. For ELISA, briefly, 96-well plates were coated with 
native  FimA  protein  (65  ng/we l l )  a n d  b l o c k e d  w i t h  5 %  
non-fat  dried  milk.  After  the  blocking,  culture  supernatants 
of  hybridoma  clones  were  added.  Following  incubation, 
plates were washed and AP-conjugated anti-mouse antibodies 
were added to wells. Finally, plates were incubated with the 
substrate of p-nitrophenyl phosphate and absorbance at 405 
nm was measured using ELISA reader (Packard Instrument, 
Downers Grove, IL). The isotype of antibodies produced from 
stabilized hybridoma clones was determined using isotyping 
k i t  a c c o r d i n g  t o  t h e  p r o t o c o l  s u g g e s t e d  b y  t h e  s u p p l i e r .
    Western  blot  analysis  was  conducted  using  two  different 
conditions of antigen preparation were used to determine the 
specificity of the antibodies. In order to prepare monomeric 
FimA, FimA protein was incubation at 100
oC for 10 min in 
a  sample buffer  containing 60 mM  Tris-HCl,  2% SDS, 0.1% 
bromophenol blue, glycerol and 2-mercaptoethanol. In order 
to prepare partially depolymerized FimA, FimA protein was 
incubated  at  80
oC  for  5  min  in  a  sample  buffer  without  2-
mercaptoethanol.  Two  micrograms  per  well  of  prepared 
FimA proteins were loaded and separated in 10% SDS PAGE. 
The resolved proteins were transferred to nitrocellulose mem-
branes  (Whatman,  Dassel,  Germany)  and  blocked  with  5% 
skim milk. The blotted membranes were incubated with hy-
bridoma culture supernatants or diluted-polysera, followed by 
incubation  with  AP-conjugated  anti-mouse  secondary  anti-
bodies.
Ascites fluid preparation
Three 12-week old male BALB/c mice were inoculated with 
0.5 ml of pristine through an intra-peritoneal injection. After 
7  days,  1×10
6  hybridoma  cell  producing  monoclonal  anti-
b o d i e s ,  w h i c h  h a d  b e e n  h a r v e s t e d  a n d  w a s h e d  i n  P B S  f o r  
twice, were injected peritoneally to induce ascites production.
Inhibition assay for bacterial attachment
Antibody-mediated inhibition of bacterial binding assay was 
performed with saliva-coated hydroxyapatite (SHA) beads as 
described in a previous study (17). Briefly, P. gingivalis 2561 
grown overnight was washed in buffered KCl twice and ad-
justed to OD600=0.1, which is equivalent to 1×10
8 CFU/ml. 
The bacterial suspension (100μl) was added to a series of 
tubes containing 2 mg SHA beads and brought to a final vol-
ume of 400μl with buffered KCl. Simultaneously, antibody 
was added to the tubes in a final dilution of 1：100, 1：200 
and  1：400.  This  mixture  was  incubated  at  room  tem-
perature. After an incubation time, the reaction mixture was FimA mAb Production
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layered  on 1 ml  of  100%  Percoll  in  a  new  siliconized  bor-
osilicate  tube  to  separate  cells  which  were  free  from  those 
bound to the SHA beads. Unbound, free P. gingivalis cells 
floating  on  the  Percoll  layer  were  removed  and  the  beads 
with bound cells and the wall of the tube were then washed.
Quantitative real-time PCR
Quantitative real-time PCR (QRT-PCR) of bacterial cells bound 
to  the  SHA  beads  was  performed  as  described  previously 
(18). Genomic DNA was extracted from the bound bacteria 
in  each  test  tube  using  DOKDO-prep
TM  Bacterial  Genomic 
DNA Purification Kit (ELPIS-Biotech Inc., Korea) and used as 
template. To obtain standard curves for QRT-PCR that relates 
bacterial concentration to Ct, the turbidity of bacterial suspen-
sion of P. gingivalis 2561 grown overnight was adjusted to 
OD600=0.1 (1×10
8 CFU/ml). For amplification of P. gingivalis 
16S rRNA gene, 3μl of each template was added to the re-
action  mixture  containing  10μl  of  iQ
TM S Y B R
Ⓡ  Green  Su-
perMix (Bio-Rad, Hercules, CA) and 250 nM of each primer, 
Pg16S-F  (TGT  TAC  AAT  GGG  AGG  GAC  AAA  GGG)  and 
Pg16S-R (TTA CTA GCG AAT CCA GCT TCA CGG), which 
were prepared based on the primer sequence published pre-
viously (19), in a final volume of 20μl. QRT-PCR was carried 
out  using  MiniOpticon
TM  Real-Time  PCR  Detection  System 
(Bio-Rad). The reaction was cycled with preliminary denatu-
ration for 5 min at 95
oC, followed by 40 cycles of denatura-
tion at 95
oC for 10 sec, annealing at 61
oC for 20 sec and pri-
mer extension at 72
oC for 30 sec. To confirm that a single 
PCR product was amplified, melting curve analysis was per-
formed  with  the  following  condition:  65
oC  to  95
oC  with  a 
heating rate of 0.2
oC per 1 sec. The amount of bacterial DNA 
in each sample was quantified by interpolation of the corre-
sponding  Ct  values  in  the  standard  curves.  Inhibitory  effi-
ciency of monoclonal antibodies was measured by determin-
ing relative percentage of DNA from the cells bound to SHA 
beads in the presence of antibody to DNA from the bound 
cells  in  the  absence  of  antibody.
Statistics
The significance of differences between means of groups was 
determined using the Student’s t-test using Sigmaplot
TM (SPSS, 
San  Rafael,  CA)  and  a  p-value＜0.05  was  considered  si-
gnificant.
RESULTS AND DISCUSSION
P. gingivalis is one of the major pathogenic microorganisms 
associated with periodontitis and fimbriae of P. gingivalis are 
responsible  for  adherence  of  the  bacteria  onto  dental  sur-
faces. In order to develop the preventive vaccine against the 
P. gingivalis through passive immunization, monoclonal anti-
bodies capable of inhibiting the binding of the bacteria onto 
dental surfaces should be developed. Consequently, we im-
munized the mice with FimA of P. gingivalis and generated 
hybridoma clones producing anti-FimA monoclonal antibody 
through fusion of spleen cells prepared from the immunized 
mice  with  Sp2/0  myeloma  cells.
    We  initially  selected  17  clones  through  ELISA.  Since  the 
fimbriae  are  FimA  subunit  polymers  composed  of  a  re-
peated-monomer  form  (20),  different  structure  forms  ap-
peared by denaturing conditions. Among those, we tried to 
select  the  hybridoma  clones  secreting  monoclonal  antibody 
with binding activity specific to native FimA (polymer form) 
not to monomer form by Western blot analysis. Interestingly, 
all selected clones were reactive to oligomer form but not to 
monomer form. We assume that the injection of native form 
of FimA efficiently stimulated the oligomer form of FimA-spe-
cific monoclonal antibody producing hybridoma cells. In ad-
dition, prescreening through ELISA in which native form of 
FimA was used as coating antigen may enrich the selection 
of hybridoma clones producing native form of FimA-specific 
monoclonal  antibody.
    This pattern of recognition is comparable to the previous 
reports of specificity of antibody against fimbriae to oligomer 
form not to monomer form (21,22). Among those clones, two 
clones, namely #123 and #256, showed high affinity to FimA 
and subjected to further characterization (Fig. 1). Monoclonal 
antibody  from  hybridoma  clone  #123  was  reactive  more  to 
FimA  oligomers  with  high  molecular  weight  than  FimA 
oligomers with low molecular weight. When we determined 
the isotypes of the monoclonal antibody, #123 clone was de-
termined to produce monoclonal antibody with IgG2b/kappa 
isotype  and  #256  clone  determined  to  produce  monoclonal 
antibody  with  IgG1/kappa.  In  addition,  binding  activity  of 
#265 clone  was  turned out  to  be  greater than that of #123 
clone. These results suggested that hybridoma clones secret-
ing monoclonal antibody specific to oligomer form of FimA 
are  generated.
    In  order  that  the  monoclonal  antibody  could  be  used  as 
vaccine through passive immunization, the monoclonal anti-FimA mAb Production
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Table I. Inhibitory effect of ascites fluid on the binding of p. 
gingivalis to saliva-coated hydroxyapatite beads
Dilution factor
Inhibition of bacterial binding (%)
# 123 # 265
1：100 71.2±5.15* 73.4±2.15*
1：200 44.1±11.65* 49.0±1.29*
1：400 29.5±9.38* 41.5±5.42*
*p＜0.05.
Figure 1. Binding activity of anti-FimA monoclonal antibodies. The two
conditions for sample preparation were applied to display FimA antigen
in Western blot analysis by incubating the strips with polyclonal 
antibody (1：5,000) prepared from the mice injected with FimA. (A)
Monomerized FimA protein was prepared by treating protein with 
100
oC for 10 min in the absence of 2-ME and display through gel 
electrophoresis. (B) Partially depolymerized FimA protein was prepared
by treating protein with 80
oC for 5 min in the presence of 2-ME. Lane
PC is purified bacterial FimA. Lane M is Prestained Protein Ladder 
(Fermentas, Glen Burnie, MD). Lane 1 is culture supernatant from #123
hybridoma clone. Lane 2 is culture supernatant from #256 hybridoma 
clone. The arrow indicated the size of FimA monomer of about 43 kDa.
body has the activity to inhibit the binding of  P. gingivalis 
onto dental surfaces. For determination of the inhibitory effi-
ciency of monoclonal antibodies against P. gingivalis binding, 
we applied the in vitro model system using saliva-coated hy-
droxyapatite (SHA) beads (17). When we prepared the ascites 
fluid and add the diluted ascites fluid into the reaction sol-
ution, efficiently inhibited the adherence of the bacteria onto 
bead surfaces (Table I). For example, 400-fold diluted mono-
clonal antibodies from #123 and #256 hybridoma clones sig-
nificantly inhibited the binding of the bacteria onto bead sur-
faces of 29.5% and 41.5%, respectively. However, control as-
cites fluid did not inhibited the binding of the bacteria onto 
SHA beads and recorded 0% inhibition rate (data not shown). 
Usually,  there  are  a  lot  of  unkown  factors  in  ascites  fluid. 
Therefore, further experiments should be performed to clearly 
characterize the nature of monoclonal antibody-mediated in-
hibition  of  bacterial  binding.  Nevertheless,  it  could  be  as-
sumed that the monoclonal antibodies produced from the es-
tablished hybridoma are able to efficiently inhibit the bacterial 
attachment since the control ascites fluids which were pro-
duced  by  using  hybridoma  clones  with  unrelated  specific.
  Collectively, these results suggested that we successfully es-
tablished the hybridoma clones producing monoclonal anti-
body specific to FimA of P. gingivalis and capable of interfer-
ing  with  interaction  between  SHA  beads  and  the  bacteria. 
Monoclonal  antibodies  could  be  produced  through  several 
different  production  processes.  We  are  currently  trying  to 
produce monoclonal antibody with safe and economical way 
including  antibody-gene  transformed  plant  cell  suspension 
culture. Therefore, we cloned the antibody genes and con-
firmed  authenticity  of  the  cloned  antibody  genes  through 
binding  assay  with  antibodies  produced  from  the  antibody 
gene-transfected CHO cells (manuscript in preparation). We 
are currently introducing the cloned antibody genes into plant 
expression vector to produce the antibody through plant cell 
suspension  expression  system.
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